Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Italy Fines Apple €98.6 Million Over App Store Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
STAMFORD, Conn., July 27, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 3, 2017, at 4:30 p.m. ET to report second quarter 2017 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 57769313. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pruritus and pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
